Stock IMNN IMUNON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Imunon, Inc.

Equities

IMNN

US15117N6022

Market Closed - Nasdaq
Other stock markets
 03:39:45 2024-06-04 pm EDT 		5-day change 1st Jan Change
1.33 USD -6.99% Intraday chart for Imunon, Inc. -9.52% +95.59%
May. 20 Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024 CI
May. 13 Transcript : Imunon, Inc., Q1 2024 Earnings Call, May 13, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Imunon : Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting entitled “A Phase II Study Evaluating the effect of IMNN-001 on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemother
PU
Imunon : Management Change/Compensation - Form 8-K
PU
Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024
CI
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
AQ
Transcript : Imunon, Inc., Q1 2024 Earnings Call, May 13, 2024
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
AQ
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
CI
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
AQ
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024
CI
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024
CI
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
AQ
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine
MT
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
DJ
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
AQ
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
CI
IMUNON Reports Compliance with Nasdaq Listing Requirements
AQ
HC Wainwright Adjust Price Target on Imunon to $13 From $12, Keeps Buy Rating
MT
Top Midday Gainers
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMNN Stock
  4. News Imunon, Inc.